Cargando…
Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management
Engraftment syndrome (ES) is a non-infectious complication seen both in autologous and allogeneic hematopoietic stem cell transplants and is characterized by the presence of non-infectious fever, diarrhea, skin rash, pulmonary infiltration, pulmonary edema, and deranged renal and liver function test...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718873/ https://www.ncbi.nlm.nih.gov/pubmed/36460884 http://dx.doi.org/10.1007/s12032-022-01894-7 |
_version_ | 1784843190373711872 |
---|---|
author | Maqbool, Shahzaib Nadeem, Muhammad Shahroz, Ahmad Naimat, Kiran Khan, Imran Tahir, Hassaan Rehman, Abdur Anwer, Faiz Iftikhar, Raheel Lee, Ka Yiu |
author_facet | Maqbool, Shahzaib Nadeem, Muhammad Shahroz, Ahmad Naimat, Kiran Khan, Imran Tahir, Hassaan Rehman, Abdur Anwer, Faiz Iftikhar, Raheel Lee, Ka Yiu |
author_sort | Maqbool, Shahzaib |
collection | PubMed |
description | Engraftment syndrome (ES) is a non-infectious complication seen both in autologous and allogeneic hematopoietic stem cell transplants and is characterized by the presence of non-infectious fever, diarrhea, skin rash, pulmonary infiltration, pulmonary edema, and deranged renal and liver function tests This review will be delineating the incidence of ES, important differential diagnoses to be considered and management options. The literature search was done through various databases like PubMed, Google scholar, Cochrane library, and EMBASE. The incidence of engraftment syndrome was ranging from 8 to 50% in patients undergoing Autologous stem cell transplantation while the incidence was 10–77% in patients undergoing Allogeneic stem cell transplantation. Fever was the most commonly observed symptom of ES in both Autologous and Allogeneic stem cell transplantation while the second most frequently reported symptom was non-infectious diarrhea in patients undergoing autologous stem cell transplantation and Skin rash in patients with Allogeneic stem cell transplantation. Pro-inflammatory cytokines and immune response dysregulation were highlighted as the mechanism behind ES development. The significant difference between ES and aGVHD was observed based on cytokines, with IL-12, IL-1β, IL-6, TNF-α, and IFN-γ levels in plasma being higher in patients with ES as compared to patients with aGVHD. Intravenous methylprednisolone was used as the treatment of choice in the majority of the studies. Overall the incidence of ES was high in patients undergoing allogeneic hematopoietic stem cells transplantation. The survival in patients developing ES was less compared to those who did not develop ES. Engraftment syndrome is one of the complications following hematopoietic stem cell transplantation that need early identification, differentiation from infectious complications, and aGVHD and timely initiation of corticosteroids therapy. |
format | Online Article Text |
id | pubmed-9718873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-97188732022-12-04 Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management Maqbool, Shahzaib Nadeem, Muhammad Shahroz, Ahmad Naimat, Kiran Khan, Imran Tahir, Hassaan Rehman, Abdur Anwer, Faiz Iftikhar, Raheel Lee, Ka Yiu Med Oncol Review Article Engraftment syndrome (ES) is a non-infectious complication seen both in autologous and allogeneic hematopoietic stem cell transplants and is characterized by the presence of non-infectious fever, diarrhea, skin rash, pulmonary infiltration, pulmonary edema, and deranged renal and liver function tests This review will be delineating the incidence of ES, important differential diagnoses to be considered and management options. The literature search was done through various databases like PubMed, Google scholar, Cochrane library, and EMBASE. The incidence of engraftment syndrome was ranging from 8 to 50% in patients undergoing Autologous stem cell transplantation while the incidence was 10–77% in patients undergoing Allogeneic stem cell transplantation. Fever was the most commonly observed symptom of ES in both Autologous and Allogeneic stem cell transplantation while the second most frequently reported symptom was non-infectious diarrhea in patients undergoing autologous stem cell transplantation and Skin rash in patients with Allogeneic stem cell transplantation. Pro-inflammatory cytokines and immune response dysregulation were highlighted as the mechanism behind ES development. The significant difference between ES and aGVHD was observed based on cytokines, with IL-12, IL-1β, IL-6, TNF-α, and IFN-γ levels in plasma being higher in patients with ES as compared to patients with aGVHD. Intravenous methylprednisolone was used as the treatment of choice in the majority of the studies. Overall the incidence of ES was high in patients undergoing allogeneic hematopoietic stem cells transplantation. The survival in patients developing ES was less compared to those who did not develop ES. Engraftment syndrome is one of the complications following hematopoietic stem cell transplantation that need early identification, differentiation from infectious complications, and aGVHD and timely initiation of corticosteroids therapy. Springer US 2022-12-02 2023 /pmc/articles/PMC9718873/ /pubmed/36460884 http://dx.doi.org/10.1007/s12032-022-01894-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Maqbool, Shahzaib Nadeem, Muhammad Shahroz, Ahmad Naimat, Kiran Khan, Imran Tahir, Hassaan Rehman, Abdur Anwer, Faiz Iftikhar, Raheel Lee, Ka Yiu Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management |
title | Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management |
title_full | Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management |
title_fullStr | Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management |
title_full_unstemmed | Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management |
title_short | Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management |
title_sort | engraftment syndrome following hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718873/ https://www.ncbi.nlm.nih.gov/pubmed/36460884 http://dx.doi.org/10.1007/s12032-022-01894-7 |
work_keys_str_mv | AT maqboolshahzaib engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT nadeemmuhammad engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT shahrozahmad engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT naimatkiran engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT khanimran engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT tahirhassaan engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT rehmanabdur engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT anwerfaiz engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT iftikharraheel engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement AT leekayiu engraftmentsyndromefollowinghematopoieticstemcelltransplantationasystematicapproachtowarddiagnosisandmanagement |